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Type 2 diabetes mellitus (T2DM) is characterized by the impairment of glucose-
stimulated insulin secretion (GSIS). Across species, GSIS is differentially driven by dietary 
macronutrients. Omega-6 polyunsaturated fatty acids (PUFAs) not only inhibit GSIS, but also 
specifically reduce the mRNA and protein expression of acyl-CoA synthetase long chain isoform 
4 (ACSL4). ACSLs initiate intracellular lipid metabolism by activating non-esterified fatty acids 
through their conversion to acyl-CoAs. ACSL4 preferentially activates and channels 
arachidonate along with its metabolites towards esterification with glycerophospholipids. ACSL4 
knockdown, however, results in the accumulation of arachidonate metabolites including 
unesterified epoxyeicosatrienoic acids (EETs) that impair GSIS. We hypothesized that PUFAs 
repress ACSL4 mRNA by activating peroxisome proliferator activated receptors (PPARs). After 
stable transfection with a reporter containing the human ACSL4 promoter, Cos7 cells were 
exposed to dietary PUFAs and synthetic PPAR agonists. By examining luciferase activity, we 
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The History of Dietary Fat Consumption and the Rise of Chronic Metabolic Diseases 
Since 1975, the global prevalence of obesity and type 2 diabetes mellitus (T2DM) has 
tripled, while simultaneously cardiovascular disease has become the leading cause of death (1,2). 
Although the underlying molecular pathophysiology behind many of these chronic metabolic 
diseases is not yet fully understood, a growing number of these conditions have been linked to 
diet-mediated disturbances in glucose and lipid metabolism (3-6). The Western diet, enriched in 
saturated fats, ⍵-6 polyunsaturated fatty acids (PUFAs), salt, and refined sugar (7, 8), has been 
associated with cardiometabolic disease (9). Globalization and advances in agricultural 
technology have contributed to these dietary characteristics (6), but certain aspects of the 
Western diet, particularly the overconsumption of ⍵-6 PUFAs, can be attributed to advocacy 
efforts by the National Institutes of Health (NIH), the American Heart Association (AHA), the 
United States Department of Agriculture (USDA), and the American Diabetes Association 
(ADA) throughout the 20th century (10-14). For decades, these agencies have advocated for the 
replacement of saturated fats with PUFAs, largely based on evidence generated by the first 
comparative population-based study to relate diet and cardiovascular disease, The Seven 
Countries Study.  
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Initiated by Ancel Keys in 1958, the Seven Countries Study (SCS) aimed to examine the 
connections of both lifestyle and anthropometric measures to the risk of developing or dying 
from cardiovascular disease (CVD) (15-18). The first phase of the SCS conducted lifestyle and 
risk factor surveys of 12,763 males, 40-59 years of age, in multiple countries (seven were chosen 
for the final analysis) across 25 years. Keys ultimately reported that CVD-associated death rates 
were relatively low in countries where saturated fat comprised less than 10% of total calories 
consumed (Japan and Italy), but significantly greater in countries where saturated fat 
consumption was more than 30% of the diet (United States, Canada, and Australia) (15-18). In 
light of these results, Keys and his colleagues later published contentious epidemiologic data 
concluding that diets rich in saturated fatty acids (SFAs) lead to an increase in blood cholesterol 
levels and CVD-associated mortality, while diets high in monounsaturated fats (MUFAs) and 
PUFAs (i.e., the Mediterranean diet) reduce CVD-related deaths (15-20).    
Keys’ epidemiologic data provided a foundation for what eventually became known as 
the “diet-heart” hypothesis. The diet-heart hypothesis proposes that particular dietary 
components increase blood cholesterol levels and that an elevated blood cholesterol 
concentration is causally linked to an increased risk of coronary heart disease (CAD) (11). In 
1961, the Central Committee for the Medical and Community Program of the AHA formally 
identified SFAs as the “dietary component” responsible for CAD in a published report (11), 
citing “evidence from many countries suggests a relationship between the amount and type of fat 
consumed, amount of cholesterol in the blood, and the reported incidence of coronary artery 
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disease.” Justifying their decision with Keys’ studies among others (21-23), the AHA committee 
called for the replacement of dietary SFAs with PUFAs like linoleic acid (LA; 18:2) as a means 
of preventing atherosclerosis and decreasing the risk of heart attacks and strokes. (11).  
In the years that followed, numerous interventional clinical trials aimed to validate the 
diet-heart hypothesis (24-31). Nearly all of these studies found evidence that the replacement of 
SFAs with ⍵-6 PUFAs could lower serum cholesterol, however, data concerning the end-points 
of CAD, CVD events, and associated mortality were unclear. For example, Rose et al. 1965 (24) 
and Dayton et al. 1969 (27) confirmed the new dietary recommendations could lower total 
cholesterol, however, both trials reported increased deaths in the experimental group receiving 
LA. Further, Rose et al. described the new guidelines as “possibly harmful”. In contrast, clinical 
trials like the Oslo Diet-Heart Study (30) and the Finnish Mental Hospital Study (31) affirmed 
the effects of substituting dietary SFAs with LA, but also claimed that the substitution could 
reduce the risk of CAD and CAD-associated mortality as much as a statin (~30%).  
Throughout the 1970s, The Minnesota Coronary Experiment (29) and The Sydney Diet 
Heart Study (28) were the only two major interventional prospective randomized control trials 
(RCTs) conducted to evaluate the benefits of replacing SFAs with ⍵-6 PUFAs. The Minnesota 
Coronary Experiment (MCE, 1968-1973), led by Ivan Frantz and Ancel Keys, was the largest 
dietary trial (n=9,570) of cholesterol lowering by replacement of SFAs with vegetable oils rich in 
LA. This study was unique in that it was the only RCT to complete a postmortem assessment and 
evaluate the clinical effects of LA substitution in subgroups of women and older adults (32).  
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In the original double-blind trial of the MCE, the interventional and control groups diets 
contained the same amount of fat (39%), but the fat composition of each diet differed. The 
control group diet contained 18% saturated fat, 5% polyunsaturated fat, and 16% 
monounsaturated fat, while the interventional group diet was 9% saturated fat, 15% 
polyunsaturated fat, and 14% monounsaturated fat. Despite the rigor of the study, only a partial 
report published in 1989 showed there was a larger reduction in mean serum cholesterol for the 
interventional group compared to the control group (29). This study did not report the effects of 
the serum cholesterol lowering in prespecified subgroups, associations between longitudinal 
changes in serum cholesterol and risk of death, or the effects of the intervention on any autopsy 
endpoints (32).  
The Sydney Diet Heart Study (SDHS, 1966-1973) was another interventional RCT 
published without complete results (28, 33). The SDHS followed 458 men aged 30-59 years with 
a recent coronary event (myocardial infarction, acute coronary insufficiency, or angina) that were 
either randomized to a diet enriched in LA or to continuation of their habitual diet. Although the 
SDHS aimed to evaluate the cardiovascular effects of replacing SFA with LA from safflower oil, 
deaths due to CVD and CAD were not documented in the 1978 analysis (28). Instead, the SDHS 
only reported all-cause mortality and noted that while the survival was slightly better in the 
control group, “multivariate analysis showed that none of the dietary factors were significantly 
related to survival.” Taken together with other studies of the time, it is clear that the data 
surrounding the AHA’s 1961 dietary recommendations were largely inconsistent. However, 
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support for the diet-heart hypothesis continued to dominate nutrition policy and health 
guidelines in the decades that followed.  
In 1977, the first comprehensive statement from the United States government (Dietary 
Goals for the United States) on risk factors for chronic disease in the American diet was 
published by the U.S. Senate Select Committee on Nutrition and Human Needs chaired by 
Senator George McGovern (34). In Dietary Goals for the United States, one of the six 
recommendations made by the committee echoed the 1961 AHA report by calling for the need to 
“reduce saturated fat consumption to account for about 10% of total energy intake; and balance 
that with poly-unsaturated and mono-unsaturated fats, which should account for about 10% of 
energy intake each.” Influenced by lobbyists and the politics of the time, the committee 
ultimately made its decisions using solely observational data emphasizing the immediate 
cholesterol-lowering effects of the AHA recommendation rather than those warning of 
detrimental long-term clinical outcomes (35).  
Dietary Goals for the United States was the last act of the U.S. Senate Select Committee 
on Nutrition and Human Needs, but the report had a significant effect on future policy within 
other departments of the federal government (35). From 1980 to the present, the United States 
Department of Agriculture (USDA) and the Department of Health and Human Services (DHHS) 
have continued to promulgate the diet-heart hypothesis through its recommendations in Dietary 
Guidelines for Americans (36). As these recommendations have become the cornerstone of U.S. 
dietary advice, the annual consumption of ⍵-6 PUFA rich oils has steadily increased from 1 
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kilogram per person to over 11 kilograms per person since 1960 (37) in parallel with the soaring 
rates of obesity, T2DM, and CVD (1, 2, 6, 8, 9).   
Current Dietary Fatty Acid Recommendations: A Review of the Evidence 
U.S. health agencies have claimed dietary advocacy efforts have made Americans 
healthier, yet there is substantial evidence that contradicts the diet-heart hypothesis as well as the 
benefits of diets substituting SFAs with ⍵-6 PUFAs (24, 26, 27, 32, 33, 38-41). For example, 
numerous reports evaluating the SCS (42-44) have called into question Keys’ methodology, 
statistical analysis, and conclusions. Chief among these issues are concerns of selection bias 
whereby some (42, 43) have claimed that Keys selected specific countries to fit his hypothesis.  
In particular, the inclusion of data from countries that Keys excluded provides a less compelling 
argument that fat consumption alone drives heart disease (see Figure S1 in appendix).  
In addition to the weaknesses of the SCS, observational studies have consistently agreed 
that the intake of SFAs is not independently associated with the incidence of CVD (48-51). 
These same analyses have also been unable to consistently demonstrate that there is an inverse 
relationship between ⍵-6 PUFA consumption and the incidence of CVD, another fundamental 
component of the diet-heart hypothesis. Further, meta-analyses of current observational trials do 
not support the conclusion that the substitution of dietary SFAs with LA reduces the risk of CAD 
and CVD (48-51). Since the early 1950s, several studies (21, 22) have suggested that SFAs and 
ω-6 PUFAs are primary antagonistic drivers of total cholesterol (total-C) and thus mediate the 
development of CAD and CVD. This approach, however, is outdated as current meta-analyses 
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(41) have identified the total-C: HDL-C ratio as the most predictive factor of CAD, suggesting 
that it is even twice as predictive as total-C. 
U.S. health agencies have also referenced several RCTs in their support of the diet-heart 
hypothesis, but these studies have drawn criticism (45). As recently as 2017, the AHA has 
continued to cite the Finnish Mental Hospital Study as evidence that the substitution of dietary 
SFAs with ⍵-6 PUFAs can significantly reduce the risk of developing heart disease (46). Recent 
re-examination of the RCT has revealed that it was poorly controlled. The Finnish trial found 
that patients in the interventional group (substitution of SFA with LA) had reduced serum 
cholesterol as much as a statin treatment and improved survival outcomes when compared to 
controls (SFA only) but, the study patients were not randomly assigned, thus introducing 
confounding factors that obscured the interpretation of the data (31). Further, thioridazine was 
disproportionately given to the control group and this antipsychotic medication has been 
associated with sudden cardiac death (31, 47). Collectively, the study’s weaknesses and 
uninterpretable results have led to its exclusion from all major review papers since 2014 (45), yet 
health agencies like the AHA have not followed suit.  
Finally, re-evaluation of the incomplete interventional RCTs conducted during the 1970s 
(The MCE and SDHS) and their subsequent publication with complete data has only continued 
to weaken the tenets of the diet-heart hypothesis. As a co-principal investigator of the MCE, 
Ancel Keys hoped to provide strong clinical evidence in favor of his hypothesis, yet the complete 
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results of the MCE were not revealed until 2016 even though the RCT finished data collection in 
1973.  
Long after Keys’ death, Chris Ramsden re-examined the raw MCE data and not only 
found that the study’s evidence provided support for the replacement of SFA in the diet with LA 
as a mechanism to lower serum cholesterol, but that such dietary changes did not result in a 
lower risk of all-cause mortality or CVD-associated death (32). In fact, Ramsden et al. found that 
the risk of CVD events and CVD-associated mortality in the MCE interventional group (diet 
containing 9% saturated fat, 15% polyunsaturated fat, and 14% monounsaturated fat), were 
increased by 22% for each 30 mg/dL reduction in serum cholesterol. Additionally, Ramsden re-
evaluated unpublished data from the SDHS where it was found that after follow-up (median of 
39 months), the SDHS interventional group that received LA, had a 13% reduction in serum 
cholesterol, but also an increased risk of all-cause (17.6%), CAD- (16.3%), and CVD-associated 
(17.2%) mortality compared to controls (33). Taken together, the complete results of the MCE 
and SDHS interventional RCTs, combined with the findings of previous observational studies 
(15-23) and current meta-analyses (48-51), suggest that replacing SFAs with ⍵-6 PUFAs 
ultimately put individuals at a greater risk of CAD events, CAD mortality or total mortality.  
The Unintended Consequences of Dietary Fatty Acid Recommendations  
While emerging data has started to shift the paradigm on dietary fat consumption, studies 
focusing on biochemical evidence to address the diet-heart hypothesis have shown that the 
substitution of SFAs with ⍵-6 PUFAs can have unintended metabolic consequences (38-40, 51-
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53). LA, the most common ⍵-6 PUFA in the Western diet, serves as a direct precursor to 
bioactive oxidized LA metabolites, endocannabinoids, and inflammatory eicosanoids that can 
have significant effects on human health (54, 55). For example, in the blood, LA makes LDL 
more susceptible to lipid peroxidation (57), and this has been shown to encourage the 
transformation of circulating monocytes into macrophages that later form foam cells in the 
arterial wall, a hallmark of atherosclerosis (56-58). Implications of diets rich in LA have also 
been described by several studies across different species (38, 39, 59, 60) and the emerging 
consensus appears to be that large quantities of dietary LA and its metabolites can exacerbate 
cardiovascular disease, cancer, and inflammation by amplifying the oxidative degradation of 
lipids in the body (55, 57).  
Besides enhanced free radical generation, the substitution of dietary SFAs with 
unsaturated FAs has been reported to contribute to the pathogenesis of obesity and diabetes. In a 
review by Katan et al. (38), researchers addressed the effects of substituting dietary SFAs with 
unsaturated FAs, like olive oil (MUFA, mostly 18:1). While these changes resulted in a 
favorable lipoprotein profile in humans when compared to replacement of fat by carbohydrates, 
the investigators also concluded that oil-enriched diets could lead to obesity. These outcomes 
have been confirmed in other species (39, 60), but some investigators have found that these diets 
are even more obesogenic and diabetogenic than saturated fat and fructose (39). In summary, 
these studies (38-40, 51-53, 55-60) provide significant biochemical evidence that current dietary 
recommendations are likely harmful, rather than beneficial.  
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Metabolism of Polyunsaturated Fatty Acids   
As the metabolic effects of ⍵-6 PUFA consumption have become clearer, interest has 
increased in understanding the mechanisms by which dietary PUFAs influence human health. 
PUFAs comprise two categories (⍵-3 and ⍵-6) and are defined according to the position of the 
first desaturation in their alkyl chains. These groupings of PUFAs are not only found in vastly 
different foods, but there has been increased recognition that PUFAs have species-dependent 
properties that are associated with potentially divergent clinical effects (52, 53). To understand 
these biological ramifications on the body, however, it is important to first summarize how 
PUFAs are metabolized by the cell.  
In mammals, intracellular metabolism of fatty acids (FA) begins with the rate-limiting 
ATP-dependent acyl-CoA synthetase (ACS)-mediated thioesterification with coenzyme A (CoA) 
to produce an acyl-CoA (61, 62). Despite the substantial diversity of fatty acids utilized by the 
cell, the majority are activated by long chain acyl-CoA synthetases (ACSLs) (58). Long-chain 
FAs (C12-22) are converted to long-chain acyl-CoAs by one of five long-chain acyl-CoA 
synthetase isoforms (ACSL1, -3, -4, -5, -6) (62, 63). Each ACSL isoform is encoded by a 
separate gene and can be functionally differentiated by its FA chain length preference, tissue 
distribution and subcellular location, attributes that alter the ability of an individual ACSL to 
channel FA towards disparate fates (see Figure S2 in appendix) (63).  
As primarily membrane bound proteins, ACSL isoform cellular localization and substrate 
preference can provide an indication as to how and where their FA substrates will be 
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metabolized. Although ACSL isoforms are ubiquitously expressed, ACSL enzymes differ in 
their tissue and cellular expression as well as substrate preference. For example, ACSL1 is 
predominantly found in the liver, ACSL3 in the testis, ACSL4 in the brain, adrenal glands and 
other steroid producing organs, ACSL5 in the small intestine, and ACSL6 in both neural cells 
and the brain (62).  At the cellular level, ACSL1, -5, and -6 are primarily associated with the 
mitochondria, plasma membrane, and cytoplasm, while ACSL3 is found in the endoplasmic 
reticulum (ER) and ACSL4 in both peroxisomes and ER (61, 62). ACSL isoforms are peripheral 
membrane proteins that utilize a wide variety of saturated and unsaturated FAs with chain 
lengths of 8-22 carbons, however, there are considerable differences between the isoforms in 
terms of substrate specificity. Current evidence suggests that ACSL1, -3, -5, and -6 prefer 
saturated fats like palmitate, while ACSL4 prefers arachidonate (61-63).   
Acyl-CoAs generated by ACS activity are precursors to a number of important signaling 
molecules such as eicosanoids (62, 63). These molecules have a range of physiological functions 
and their downstream effects are largely dependent upon the relative concentration of upstream 
PUFA species (52). The ⍵-6 and ⍵-3 PUFAs are not interconvertible and once in the 
intracellular environment, must compete for elongation and saturation by the same enzymes in 
order drive metabolic processes (64). For example, studies of fish oil supplements in healthy 
human subjects show that long chain ⍵-3 PUFAs are capable of inhibiting inflammatory 
networks involving leukocyte chemotaxis, adhesion molecule expression, and anti-inflammatory 
cytokines (65). Additionally, ⍵-3 PUFA-derived eicosanoids give rise to important inflammation 
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resolving mediators known as resolvins, protectins, and maresins (65). In contrast, an abundance 
of dietary ⍵-6 PUFAs and their metabolites have been shown to be associated with the 
stimulation of inflammatory pathways and production of thromboxanes, leukotrienes, and 
prostaglandins that are prothrombotic and proaggregatory (66). 
Arachidonic Acid Partitioning and Glucose-Stimulated Insulin Secretion  
The ⍵-6 PUFA, arachidonic acid (AA; 20:4), is the parent compound of the 
inflammatory eicosanoids (67). In the diet, AA is primarily found in animal-derived products 
like red meat, poultry, eggs, fish, and dairy foods as plants cannot generate these particular 
PUFAs (66). AA can also be readily synthesized from dietary LA by a series of elongases and 
desaturases (67). When preferentially activated by ACSL4 (68), AA and its metabolites serve as 
important mediators of cellular signaling involved in vasodilation, ion channel activation, 
angiogenesis, mitogenesis, anti-inflammatory responses, and hormone secretion across multiple 
cell types (67, 69). As a bridge linking nutrient metabolism to immunity and inflammation, AA 
thus holds a key role in the emergence and progression of chronic metabolic diseases.  
In T2DM, in vitro (70, 71) and in vivo (72-74) studies have demonstrated that dietary and 
infused ⍵-6 PUFAs like AA and its precursor LA can contribute to the disease by impairing 
glucose-stimulated insulin secretion (GSIS). The underlying mechanisms are not entirely clear, 
but our lab’s data suggest that the partitioning of intracellular unesterified AA is integral to this 
process. Unesterified AA can be a substrate for eicosanoid-producing enzymes like 
lipoxygenases, cyclooxygenases, and cytochrome P450 monooxygenases (CYP), or it can be 
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thioesterified with CoA by ACSL4 where the resultant product, AA-CoA, can be re-esterified 
back into glycerophospholipids (75). ACSL4 has a critical physiological function at this juncture 
as CYP metabolites like epoxyeicosatrienoic acid (EETs) result in the inhibition of GSIS, while 
the ACSL4-mediated diversion of AA away from eicosanoid-producing enzymes preserves GSIS 
(71).  
We have previously shown that AA or LA exposure in INS 832/13 rat insulinoma beta-
cells specifically reduces ACSL4 mRNA expression and ACSL4 protein expression, resulting in 
as much as a 40% reduction in GSIS (71). Given that ⍵-6 PUFA rich oils continue to be more 
prominent in the Western diet (37), PUFA-mediated changes in ACSL4 expression and its 
resulting effects on GSIS represent a potential molecular mechanism coupling the unintended 
consequences of current dietary FA recommendations to the pathogenesis of T2DM. 
Unfortunately, few studies have examined the role of PUFA-mediated impairment of GSIS 
through the lens of ACSL4 transcription, and thus the primary objective of this work was to 
determine how these dietary FAs could contribute to T2DM and other cardiometabolic diseases 
through their effects on the expression of this critical enzyme.  
Nutrigenomics of Polyunsaturated Fatty Acids   
There is a considerable body of evidence that PUFAs like AA have the capacity to 
directly regulate metabolic processes by influencing the expression of enzymes, receptors, 
hormones, and other proteins. Important enzymes involved in lipogenesis, glycolysis, and 
glucose transport have all been implicated as target genes of AA-mediated regulation in cellular 
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environments (76). For example, in hepatocytes, AA and its precursor LA downregulate the 
activity of fatty acid synthase (77), acetyl-CoA carboxylase (77), and glucose kinase (78). In 
cultured adipocytes, AA and LA exposure can alter the isoform expression of glucose 
transporters by inducing GLUT1 and repressing GLUT4 expression (79). These experiments (69-
72, 76-79) highlight how PUFAs can function as potent regulators of metabolism at both cellular 
and whole-body levels.  
In the cell, PUFAs exert their regulatory abilities through a variety of transcriptional, 
translational, and post-translational mechanisms. At a transcriptional level, PUFAs can bind to 
and regulate the activity of transcription factors that are members of the peroxisome proliferator-
activated receptor family (PPARs), liver X receptor family (LXRs), retinoic acid receptor family 
(RXRs), and hepatic nuclear factor-4 family (HNF-4s) (77). When bound, PUFAs activate these 
nuclear receptors to enhance or inhibit the transcription of their target genes (78).  PUFAs 
control gene expression at a translational and posttranslational level by inhibiting the formation 
of the translation initiation complex (80) and by promoting the degradation of target proteins via 
the ubiquitin-proteasome system (81, 82).  
The present study focuses on the action of PPARs in order to address the PUFA-mediated 
transcriptional regulation of ACSL4. Three subtypes of PPARs (PPARɑ, PPARβ/𝛿, and PPAR𝛾) 
have been identified and studied in vertebrates for their critical role in the transcriptional control 
of genes involved in metabolic diseases (83). PPAR subtypes are physiologically distinct in 
terms of their involvement in metabolic pathways. For instance, PPARɑ plays a major role in 
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lipid oxidation and inflammation (77), while PPAR𝛾 regulates adipogenesis and glucose 
metabolism. PPARβ/𝛿 is the least studied isoform, but it has been shown to be involved in cell 
differentiation and lipid storage alongside its role as a potent repressor of PPARɑ- and PPAR𝛾-
mediated transcription. (83-86). These multi-domain proteins were originally named for their 
ability to induce peroxisome proliferation in rodent hepatic and renal cells (87), but were later 
found to be sensors of lipophilic molecules. The lipid ligands of these nuclear receptors 
alongside dimerization with RXRs results in the activation of PPARs that bind to specific 
peroxisome proliferator response elements (PPREs) which are capable of triggering changes in 
lipid metabolism and inflammation (83). 
In their active state, PPARs can enhance or repress transcription by either binding to 
PPREs found in the promoters of target genes or through PPRE-independent mechanisms. In the 
former, regulation of gene activity is thought to occur through three possible pathways: ligand-
independent repression, ligand-dependent repression, and ligand-dependent activation (88). In 
the ligand-independent repression model, the absence of a ligand results in the binding of the 
PPAR-RXR heterodimer to co-repressors that inhibit gene expression in target genes (89). 
Similarly, repression can also occur through the ligand-dependent repression model where 
binding of a ligand to the PPAR-RXR complex induces association of co-repressors that reduce 
gene expression (88). Finally, the last PPRE-dependent mechanism PPARs can utilize to 
modulate transcription is ligand-dependent activation. In this model, the binding of an activating 
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ligand or agonist to PPAR-RXR results in the dissociation of co-repressors and recruitment of 
co-activators that enhance the transcription of target genes (88, 89).   
Experimental Aims and Hypothesis  
The concurrence of increasing trends in the consumption of ⍵-6 PUFAs and the 
worsening epidemic of metabolic and cardiovascular disease is not circumstantial, but rather 
linked to direct changes in the diet that have emerged as a result of nutrition advocacy efforts 
advocated by U.S. health agencies since the 1960s. Rooted in inconsistent and oftentimes 
contradictory evidence, dietary recommendations perpetuating the diet-heart hypothesis have 
proven themselves to be harmful, rather than beneficial to public health. Multiple epidemiologic 
studies, meta-analyses, and clinical trials have outlined the unintended consequences of diets 
substituting SFAs with ⍵-6 PUFAs, but the means by which PUFAs drive the development of 
metabolic and cardiovascular disease are still unclear. Here, we seek to unveil a potential 
mechanism through the lens of ACSL4, a key rate-limiting enzyme at the interface of lipid and 
carbohydrate metabolism. 
Several studies have already suggested that PUFA-mediated activation of PPARs can 
influence ACSL4 expression (90, 91) and we have previously shown that PUFA exposure in INS 
832/13 and Cos7 cells reduces ACSL4 mRNA. Based upon these data, we hypothesize that 
PUFAs repress ACSL4 transcription by binding to the PPAR-RXR heterodimer and induce the 
association of corepressor candidates like SMRT (silencing mediator for retinoid and thyroid 
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hormone receptors), SHARP (SMRT and histone deacetylase-associated repressor protein), and 
HDAC (class 1 histone deacetylases) at the ACSL4 promoter in a PPRE-dependent manner.  
To examine our hypothesis and determine if the PPRE plays a role in the transcriptional 
regulation of ACSL4, different FA ligands and PPAR agonists were exposed to stably transfected 
cells containing the native human ACSL4 promoter or mutant ACSL4 promoter lacking PPRE 
binding sites. By comparing luciferase activities between cell lines, we showed that specific 
ACSL4 substrates can repress ACSL4 transcription by binding to PPRE in the ACSL4 promoter. 
Further, we confirmed through both PPAR agonist exposure experiments that PPARɑ and 
PPARγ activation are specifically responsible for reductions in ACSL4 transcription. The 
outcome of this study provides insight into a mechanism by which dietary PUFAs can disrupt 


















MATERIALS AND METHODS 
Reagents 
FA-free bovine serum albumin (BSA), butylated hydroxytoluene (BHT), palmitic acid 
(PA; 16:0), and oleic acid (OA; 18:1) were purchased from Millipore-Sigma (St. Louis, MO). 
Docosahexaenoic acid (DHA; 22:6), eicosapentaenoic acid (EPA; 20:5), arachidonic acid (AA; 
20:4), linoleic acid (LA; 18:2), PPAR agonists WY-14643, clofibrate, GW0742, L-165041, and 
rosiglitazone were obtained from Cayman Chemical Company (Ann Arbor, MI). All other 
reagents were of analytical grade and purchased from Millipore-Sigma (St. Louis, MO) unless 
noted otherwise.  
Cell Lines 
Human hepatoma HepG2 and African green monkey kidney fibroblast-like Cos-7 cells 
were obtained from American Type Culture Collection (Manassas, VA). HepG2 cells between 
passage number 40 and 60 were cultured in RPMI-1640 with 10% FBS and 2 mM L-glutamine. 
Cos-7 cells between passage number 30 and 60 were cultured in DMEM with 10% FBS.  
Construction of the Human ACSL4 promoter luciferase reporters 
Reporters for the human ACSL4 promoter, derived from a DNA sequence extending the 
human ACSL4 promoter region (GenBankTM accession number NG_008053) from -2426 to +56 
relative to the 5’ end of exon 1 (Table 1), were generated from HepG2 genomic DNA
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cloned into pcDNA 3.1 Hygro (-) (Invitrogen, Carlsbad, CA) (Figure S3 in appendix). The target 
was then subcloned into pGL4.16, a luciferase reporter provided by Promega (Madison, WI), at 
the HindIII and Xho1 restriction sites to create the wild type human ACSL4 promoter reporter 
(pGL4.16-ACSL4 WT) (Figure S4A). The human PPRE knockout ACSL4 promoter reporter 
(pGL4.16-ACSL4 PPREKO) was constructed by excising PPRE sites in the pGL4.16-ACSL4 
WT reporter using Kpn1 restriction sites and religating the vector (Figure S4B). Following 
transformation and amplification in NEB® 10-beta Competent Escherichia coli (New England 
Biolabs, Ipswich, MA), clones were sequenced by Sanger sequencing (GENEWIZ, South 
Plainfield, NJ) to verify target identity and orientation (complete vector maps shown in Figure 
S5 in appendix).  
Generation of stably transfected Cos7 cell lines 
A heterogeneous population of stably transfected Cos7 cells was generated through the 
elimination of all non-transfected cells via hygromycin B selection. To determine the optimal 
hygromycin B concentration required for selection, a kill curve was conducted (see Figure S6 in 
appendix). Non-transfected cells were subjected to increasing concentrations of Hygromycin B 
to determine the minimum amount required to kill all cells over the course of 2 to 7 days. 
Following a kill curve, pGL4.16 (empty vector), pGL4.16-ACSL4 WT, and pGL4.16-ACSL4-
PPRE-KO reporter vectors were stably transfected into separate Cos7 cell lines using the Xtreme 
HP DNA transfection protocol provided by Millipore-Sigma (St. Louis, MO). Transfected Cos7 
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were subsequently subjected to selection by DMEM containing 400 µg/mL Hygromycin B and 
10% FBS for 14 days prior to PUFA exposure. 
FA loading of the cells 
200 mM FA stock solutions of PA, OA, LA, AA, EPA, and DHA were dissolved in 
100% EtOH. These stocks were then made into 5 mM FA working solutions by combining an 
equal volume of autoclaved H2O with the 200 mM FA stock, adding BHT as an antioxidant 
(final concentration of 1 mM), and diluting with additional autoclaved H2O. Similarly, 5 mM 
working solutions of the vehicle were generated by mixing equal volumes of EtOH and H2O 
before adding BHT and diluting with autoclaved H2O. Working solutions were subsequently 
conjugated to BSA (1:1 molar ratio) in order to increase the solubility of the free FA and prepare 
solutions in the physiological concentration range as recommended in the literature (92). After 
conjugating the FAs with BSA for 30 minutes at 37o C, working solutions were filter sterilized 
and stored at -20o C. Cos7 cells were incubated for 24 hours in DMEM containing 10% FBS 
before FA were added to the media (final concentration of 50 µM). FA concentrations were 
selected in order to induce the maximum cellular response following AA exposure as previous 
reported (92, 93). After exposure, cells were supplied with fresh media supplemented with 
prescribed FA every 24 hours.  
Luciferase reporter assay 
Luciferase reporter assays were performed using the Luciferase Assay System from 
Promega (Madison, WI) according to the manufacturer’s protocol. This assay produces light by 
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converting the chemical energy of luciferin oxidation through an electron transition, thus 
forming oxyluciferin. Firefly luciferase catalyzes this oxidation reaction in an ATP-dependent 
manner and the amount of light produced is directly proportional to promoter activity.  
After selection, stably transfected Cos7 cells were exposed to DMEM containing the 
vehicle, PA, OA, LA, AA, EPA, or DHA for 24- to 72-hours. Prior to the addition of luciferase 
assay reagent and measurement of firefly luciferase activity, cells were gently washed with PBS 
pre-warmed to 37ºC and lysed with 20 µL of lysis mix containing 1X luciferase cell culture lysis 
reagent (25 mM Tris-phosphate (pH 7.8), 2 mM dithiothreitol, 2 mM 1,2-diaminocyclohexane-
N, N, N ́, N ́-tetraacetic acid, 10% glycerol, 1% Triton® X-100), 1.25 mg/mL lysozyme, and 2.5 
mg/mL BSA. Triplicate wells were assayed for each condition using a SynergyTM HT multi-
mode microplate reader (BioTek, Winooski, VT). Luciferase activity was measured by 
luminescence and subsequently normalized to the empty pGL4.16 vector.  
Effect of PPAR agonists on ACSL4 transcription 
Working solutions of WY-14643 (PPARɑ agonist, 2.5-10 µM), Clofibrate (PPARɑ 
agonist, 20-110 µM), GW0742 (PPAR δ/β agonist, 0.5-2 µM), L-165041 (PPAR δ/β agonist, 25-
100 µM) and Rosiglitazone (PPAR 𝛾 agonist, 10-100 µM) were dissolved in DMSO and filter 
sterilized. These specific concentrations were selected for exposure in order to outline the 
minimal and maximal responses expected for each agonist as well as to compare their regulatory 
effects with those reported in the literature. Stably transfected Cos7 cells were incubated in 
DMEM containing 10% FBS for 24 hours prior to the addition of PPAR agonists. Following 
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exposure, luciferase activity was measured for triplicate wells in each condition, normalized to 
the empty pGL4.16 vector, and expressed as a fold of luciferase activity from cells only exposed 
to the vehicle.   
siRNA Transient Transfection 
Duplex siRNAs were designed and synthesized by Integrated DNA technologies 
(Coralville, IA). Targets against human RXRɑ (GenBankTM accession number NM_002957) 
included those in the 3’ untranslated region as well as coding segments. A nonspecific siRNA 
provided by IDT functioned as a control (Table 2). Stable Cos7 cells were transfected with 
DharmaFect reagent 1 (Dharmacon Products, Lafayette, CO) as suggested by the manufacturer 
for a final duplex siRNA concentration of 25 nM. Stable Cos7 cells were seeded at a density of 
4.0 x 104 cells/mL and then incubated for 24 hours prior to treatment with siRNAs for 24 hours. 
24 hours post-transfection, cell medium was refreshed and subsequent exposure experiments 
were conducted.  
Analysis of siRNA Transfection by RT-qPCR  
Total RNA was extracted from stable Cos7 cells using TRIzol (Invitrogen, Carlsbad, CA) 
before being reverse transcribed by a high-capacity cDNA archive kit (Applied Biosystems, 
Foster City, CA). The resulting cDNA was then amplified by RT-qPCR in a total reaction 
volume of 25 µL using Absolute QPCR Sybr Green Fluorescein Mix (ThermoScientific, 
Waltham, MA). Amplifications were conducted in an iCycler detection system (Bio-Rad, 
Hercules, CA). The primers used are listed in Table 3. Human RXR⍺ expression was normalized 
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to endogenous hypoxanthine-guanine phosphoribosyltransferase (HPRT1, GenBankTM accession 
number NM_000194).   
Statistical analysis 
Data are presented as mean ± SEM. Differences between experimental conditions were 
first evaluated by Levene’s test to confirm equal variance, followed by a one-way ANOVA. If 
the results were significant, a post hoc analysis was performed using a pairwise t-test with 
Bonferroni’s correction. Results were deemed statistically significant if p-values following 
















PUFA-mediated Reductions in ACSL4 Transcription are PPRE-dependent in Cos7 Cells 
To evaluate the role of dietary lipids in the transcriptional regulation of human ACSL4, 
we constructed 2 luciferase reporter vectors containing the human ACSL4 promoter: pGL4.16-
ACSL4-WT (Figure S5B, -2426 to +56 relative to the transcription start site (TSS), 5 PPRE 
motifs), and pGL4.16-ACSL4-PPREKO (Figure S5D, -1162 to +56 relative to the TSS, PPRE 
motifs removed). PCR primers used for amplicons are listed in Table 1. In addition to our 
promoter variants, each reporter encoded a complete transcript of the synthetic firefly luciferase, 
Luc2CP (GenBankTM accession number AAW66988O), as well as a selectable marker for 
hygromycin resistance. ACSL4 transcription was assessed by measuring quantitative changes in 
bioluminescence, a byproduct of the Luc2CP-mediated oxidative decarboxylation of D-luciferin. 








25 -2426 to -2401 GGTAGTTCTGGGTAGGACTCATTAC 
ACSL4 Promoter 
Reverse 
18 +38 to +56 CTGGCACTCGGAAAGCTC 
 Promoterless pGL4.16 (control), pGL4.16-ACSL4-WT, and pGL4.16-ACSL4-PPREKO 
were individually transfected into Cos7 cells. Following 2 weeks of selection with Hygromycin 
B (400 µg/mL), a heterogeneous population of stably transformed Cos7-pGL4.16, Cos7-ACSL4-
WT and Cos7-ACSL4-PPREKO cell lines were generated for consistent long-term luciferase 
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expression. Cos7-pGL4.16, Cos7-ACSL4-WT, and Cos7-ACSL4-PPREKO were then 
challenged with albumin-conjugated 50 µM FA (either PA, OA, LA, AA, EPA, DHA) or EtOH: 
H2O vehicle for 24- to 72-hours. After exposure, Luc2CP luciferase activity in each condition 
was normalized to the Cos7-pGL4.16 control in order to serve as a reference for basal reporter 
activity. To compare changes in luciferase activity in Cos-ACSL4-WT and Cos7-ACSL4-
PPREKO cell lines, each FA condition was compared to the vehicle.  
After 24-, 48-, or 72-hours, luciferase activity in Cos7-ACSL4-WT cells exposed to 50 
µM LA, AA, DHA, or EPA were significantly reduced when compared to the vehicle, indicating 
PUFAs regulate ACSL4 transcription through the ACSL4 promotor (Figure 1). As the duration of 
PUFA exposure did not have an effect on ACSL4 promoter luciferase activity, this suggests that 
ACSL4 expression does not return to wild-type levels as long as PUFAs are metabolized by the 
cell. Further, luciferase activity in Cos7-ACSL4-WT cells challenged with a saturated fatty acid 
(PA) or monounsaturated fatty acid (OA) did not differ from cells exposed to vehicle. These data 
are consistent with our lab’s previous reports that PUFAs, but not SFAs and MUFAs, 
specifically reduce ACSL4 mRNA expression in INS 832/13 and Cos7 cells.  
Unlike the Cos7-ACSL4-WT cells, the Cos7-ACSL4-PPREKO cells contain a luciferase 
reporter (pGL4.16-ACSL4-PPREKO) without PPRE binding sites. If PUFA-mediated regulation 
of ACSL4 is PPRE-dependent, we expected that FA exposure would not have a significant effect 
on luciferase activity in Cos7-ACSL4-PPREKO as PPAR binding sites are absent. Indeed, as 
predicted, luciferase activity in Cos7-ACSL4-PPREKO was unaffected after 24-, 48-, and 72-
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hours of FA exposure, indicating the removal of PPRE motifs or other regulatory motifs in the 
distal ACSL4 promoter are critical to ACSL4 transcription (Figure 2). Furthermore, when 
compared to the vehicle control, FA type and exposure duration did not alter luciferase activity 
in Cos7-ACSL4-PPREKO cells. As a reduction in ACSL4 expression was only observed in 
Cos7-ACSL4-WT cells exposed to PUFAs (Figure 1), the results from FA exposure in Cos7-
ACSL4-PPREKO (Figure 2) suggest that PUFA-mediated changes in ACSL4 transcription in 
Cos7 cells are PPRE-dependent or regulated by components in regions of the distal ACSL4 
promoter (-2426 to -1162 relative to the TSS).  
Figure 1: ω-3 and ω-6 PUFAs reduce ACSL4 transcription in Cos7-ACSL4-WT Cells 
independent of exposure duration  
pGL4.16-ACSL4-WT luciferase activity as a fold of the vehicle after 24-, 48-, and 72-hours 




Figure 2: Removal of ACSL4 promoter PPRE sites rescues ACSL4 transcription after 
PUFA exposure * 
Luciferase activity of pGL4.16-ACSL4-PPREKO as a fold of the vehicle after 24-, 48-, and 72-
hours (mean ± SEM; n=3). 
 
*No statistically significant differences were observed through comparison tests between groups 










PPAR Isoforms Differentially Regulate ACSL4 Transcription in Cos7 cells 
 PUFA exposure experiments with stably transfected Cos7 cell lines provide evidence 
(Figure 1 and Figure 2) that PUFA-mediated reductions in ACSL4 transcription are PPRE-
dependent. We reasoned that binding to the PPRE of the ACSL4 promoter by a specifically 
activated PPAR would result in the same PPRE-dependent PUFA-mediated reduction in ACSL4 
transcription. Therefore, to further evaluate the regulatory actions of PPARs on ACSL4 
transcription, we sought to identify which PPAR isoform(s) (PPARɑ, PPARβ/𝛿, and PPAR𝛾) 
could reduce ACSL4 transcription after activation by a synthetic ligand.  
PPAR⍺-mediated Downregulation of ACSL4 is PPRE-dependent in Cos7 Cells  
The effects of PPAR⍺ on ACSL4 transcription were evaluated by exposing Cos7-ACSL4-
WT and Cos7-ACSL4-PPREKO cells to either one of two PPAR⍺ agonists (20-110 µM of 
clofibrate or 2.5-10 µM of WY-14643) and comparing to those only exposed to dimethyl 
sulfoxide (DMSO). Specific concentrations were selected to outline the minimum and maximum 
responses expected for each agonist activating PPAR⍺; Clofibrate has an EC50 of 55 μM and 
∼500 μM for PPARα and PPARγ, respectively, while WY-14643 has an EC50 of 5.0 μM, 60 μM, 
35 μM for human PPARα, PPARγ and PPARβ/δ, respectively (107). All cells were exposed to 
agonists for 24 hours before luciferase activity was evaluated in order to compare the regulatory 
effects of activated PPARs with the previously observed PUFA-mediated repression of ACSL4 
transcription (Figure 1).  
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After treatment with either clofibrate (Figure 3A) or WY-14643 (Figure 3B), luciferase 
activity in Cos7-ACSL4-WT cells was dose-dependent and inversely correlated with 
concentration, indicating that the Cos7-ACSL4-WT reporter is negatively regulated by PPAR⍺ 
agonists. Further, when compared to clofibrate, lower concentrations of WY-14643 were needed 
to reduce luciferase activity in Cos7-ACSL4-WT cells, data consistent with reports identifying 
WY-14643 as a more potent agonist of PPAR⍺ than clofibrate (95).	In contrast to Cos7-ACSL4-
WT cells, luciferase activity in Cos7-ACSL4-PPREKO cells was unaffected by exposure to 
either clofibrate (20-110 µM) (Figure 3A) or WY-14643 (2.5-10 µM) (Figure 3B) when 
compared to the DMSO control, suggesting PPAR⍺’s inhibitory effects on ACSL4 transcription 
are, like PUFAs, PPRE-dependent. Together, these data provide additional evidence that ACSL4 





















Figure 3: PPAR⍺-mediated downregulation of ACSL4 transcription is PPRE-dependent  
A: Luciferase activity as a fold of the DMSO control in stably transformed Cos7 cells following 
clofibrate exposure (mean ± SEM; n=3). B: Luciferase activity as a fold of the DMSO control in 





PPARβ/𝛿 Agonists Differentially Regulate ACSL4 Transcription in Cos7 Cells  
We next aimed to determine if the PPARβ/𝛿 isoform plays a role in the transcriptional 
regulation of ACSL4. Cos7-ACSL4-WT and Cos7-ACSL4-PPREKO cells were exposed to either 
one of two PPARβ/𝛿 agonists (25-100 µM of L-165041 or 0.5-2 µM of GW0742) for 24 hours 
before luciferase activity assay. Unlike our experiments with the PPAR⍺ agonists, the 
concentrations of PPARβ/𝛿 agonists used were specifically selected so that we could compare 
our results with those previously reported in hepatocytes where the transcriptional effects of 
PPARβ/𝛿 agonists on ACSL4 had been previously examined (91). L-165041 has a Ki of 6 nM 
and ∼730 nM for PPARβ/𝛿 and PPARγ, respectively, while GW0742 has an EC50 of 1–3.5 nM, 
1.1µM, 2 μM for PPAR β/δ, PPARα, and PPARγ, respectively (108). 
In Cos7-ACSL4-WT cells, the effects of PPARβ/𝛿 agonists on ACSL4 promoter activity 
were divergent. Luciferase activity was increased in a dose-dependent manner in Cos7-ACSL4-
WT cells exposed to L-165041 (Figure 4A), but the underlying mechanism appeared to be 
PPRE-independent as no significant differences were observed between Cos7-ACSL4-WT and 
Cos7-ACSL4-PPREKO cells. For the agonist concentrations, we interpreted our results as the 
product of two possible regulatory pathways: changes in nuclear receptor binding in the proximal 
ACSL4 promoter (-1162 to +56 relative to the TSS) common to both Cos7 cell lines and/or 
nuclear receptor crosstalk between PPARβ/𝛿 and PPARγ with themselves or other transcription 
factors since both PPAR isoforms would have been activated.  	
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Contrary to the effects of L-165041 exposure, no significant differences in ACSL4 
transcription were observed in Cos7-ACSL4-WT cells exposed to GW0742 (Figure 4B), except 
for at a concentration of 1 µM, which we attributed to the co-activation of PPAR⍺ (EC50 = 1.1 
µM). All other data points were difficult to interpret as multiple PPAR isoforms could have been 
activated. For instance, while only PPARβ/𝛿 would be active at 0.5 µM of GW0742, all 3 PPAR 
isoforms would be activated at 2 µM of GW0742. Further, the activation of multiple PPAR 
isoforms could lead to downstream crosstalk with other nuclear receptors (i.e., constitutive 
androstane receptors (CARs), LXRs), which could have differing, if not competing, 
transcriptional effects. In Cos7-ACSL4-PPREKO cells, luciferase activity was unaffected by 
GW0742 exposure at all concentrations evaluated, indicating the removal of PPRE sites does not 
appear to have an effect on how PPARβ/𝛿 influences the ACSL4 transcription in Cos7 cells 
(Figure 4B). While we could have used lower concentrations of GW0742 to try to isolate the 
effects of PPARβ/𝛿, we ultimately concluded that PPARβ/𝛿 does not play a significant role in 















Figure 4: PPARβ/𝛿 agonists differentially regulate ACSL4 transcription in Cos7 cells 
A: L-165041 upregulation of ACSL4 transcription is PPRE-independent in Cos7-ACSL4-WT 
cells. Data presented as mean ± SEM (n=3) B: GW0742 exposure does not significantly affect 





PPARγ-mediated Downregulation of ACSL4 is PPRE-independent in Cos7 Cells 
Finally, to examine the effect of PPARγ on the PPAR-mediated regulation of ACSL4 we 
exposed stably transformed Cos7 cells to rosiglitazone (potent PPARγ agonist) at concentrations 
of 10 to 100 µM for 24 hours before comparing the resultant luciferase activity. Similar to our 
experiments with the PPARβ/𝛿 agonists, the concentration range of rosiglitazone used for 
exposure was selected to determine if the findings reported by Askari et al. that rosiglitazone 
represses ACSL4 protein activity are also observed at the transcriptional level (109). PPARγ 
exists in two different protein isoforms (PPARγ1 and PPARγ2) and each isoform is differentially 
expressed (PPARγ1 predominantly in adipose tissue, while PPARγ2 is ubiquitous) and activated 
by rosiglitazone (EC50s of 30 nM and 100 nM for PPARγ1 and PPARγ2 respectively) (108).   
After agonist treatment, luciferase activity in Cos7-ACSL4-WT cells was significantly 
reduced for cells exposed to concentrations of rosiglitazone greater than 10 µM, indicating the 
pGL4.16-ACSL4-WT reporter is regulated by PPARγ (Figure 5). A dose-dependent relationship 
was not observed between rosiglitazone concentration and ACSL4 promoter activity, however, 
this is likely because a high concentration of rosiglitazone was used. Under normal physiological 
conditions, less than 1µM rosiglitazone is sufficient to activate the PPARγ isoforms (94). In 
Cos7-ACSL4-PPREKO cells, neither a dose-dependent response nor normalization of ACSL4 
transcription was observed following rosiglitazone exposure (Figure 5), suggesting the PPARγ-
mediated reduction in ACSL4 transcription is PPRE-independent.  
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Several transcription factor motifs are present in the ACSL4 promoter, including those for 
RARs, LXRs, SREBP-1, ChREBP, and MLX. Although rosiglitazone does not bind to these 
nuclear receptors, activation of either PPARγ isoform could indirectly affect their expression and 
thus change ACSL4 transcription through the regulatory effects of other transcription factors. 
Thus, we concluded that PPARγ activation reduces ACSL4 transcription, but unlike the 
downregulation of ACSL4 by PUFAs or PPAR⍺ agonists, the mechanism is either PPRE-
independent or mediated by changes in nuclear receptor binding in the proximal ACSL4 
promoter (-1162 to +56 relative to the TSS, PPRE motifs absent), found in both Cos7-ACSL4-
WT and Cos7-ACSL4-PPREKO cells.  
Figure 5: PPARγ-mediated downregulation of ACSL4 is PPRE-independent 
Luciferase activity as fold of the DMSO control in Cos7 cell lines after 24 hours of rosiglitazone 




Knockdown of RXR⍺ in Stably Transformed Cos7 Cells Provided Inconclusive Evidence 
that the PUFA-mediated Reduction in ACSL4 transcription involves RXR. 
Our previous experiments in stable Cos7 cells provide evidence that PUFAs (ω-3 and ⍵-
6, Figure 1) and the ligand-activated PPAR⍺ isoform (Figure 3) can induce a PPRE-dependent 
reduction in ACSL4 transcription. While PUFA-mediated activation of PPARs is a potential 
mechanism for the transcriptional regulation of human ACSL4, correlation is not causation. 
PPARs directly exert their effects on target genes by forming obligate heterodimers with RXRs 
and subsequently binding to PPRE sites (83). Our previous data have examined the effects of 
removing PPRE sites following PUFA and PPAR agonist exposure, but we did not evaluate 
ACSL4 transcription when PPAR is unable to bind with RXR.  
In the absence of RXR, we predict that PPARs would be unable to bind to the PPRE and 
their regulatory effects would be diminished. Three RXR isoforms have been identified (RXRɑ, 
RXRβ, and RXR𝛾) in vertebrates, and they are unique among other transcription factors in that 
they can heterodimerize and homodimerize to exert their regulatory effects (94, 95). In addition, 
RXRs are promiscuous transcription factors capable of binding to numerous nuclear receptors, 
and they can be activated by a vast array of natural ligands, including PUFAs (95). To confirm 
that PPAR’s dimerization with RXR and its subsequent binding to PPRE is responsible for the 
PUFA-mediated reduction in ACSL4 mRNA, we performed a transient knockdown (KD) of 
RXR⍺ using siRNA. We anticipated that the KD of RXR⍺ would prevent the binding of PPARs 
to the PPRE in the ACSL4 promoter, and thus similar levels of luciferase activity would be 
observed in both Cos7-ACSL4-WT and Cos7-ACSL4-PPREKO cells.  
 
 37 
Duplex siRNA sequences (Table 2) were used to transiently KD RXR⍺ in Cos7 cells. To 
verify siRNA-mediated reduction of RXR⍺, total RNA from transfected cells was isolated and 
subjected to RT-qPCR. Primers used to amplify RXR⍺ and HPRT1 (housekeeping reference 
gene) are shown in Table 3. RT-qPCR results confirmed transient KD of RXR⍺ in cells exposed 
to 2 of the 3 siRNA used (13.1 and 13.2, Figure 6), with duplex siRNA 13.1 targeting the 3’ 
UTR of RXR⍺ causing the greatest reduction in RXR⍺ mRNA expression by ~85% (Figure 6). 
As a result of its KD efficiency, duplex siRNA 13.1 (siRNA13.1) was used for all subsequent 
siRNA-mediated KD experiments in stably transformed Cos7 cells.  
We next sought to evaluate the downstream effects of PUFA exposure in Cos7-ACSL4-
WT and Cos7-ACSL4-PPREKO cells transfected with siRNA13.1. As expected, luciferase 
activity in Cos7-ACSL4WT cells transfected with scramble control (Figure 7A) was consistent 
with our previous reporting that PUFAs reduce ACSL4 transcription (Figure 1). ACSL4 promoter 
activity in Cos7-ACSL4WT transfected with siRNA 13.1, however, was unaffected by PUFA 
exposure, indicating that RXR⍺ is critical to ACSL4 transcription (Figure 7A). In addition to 
examining ACSL4 transcription, we also used luciferase activity as an indicator of cell viability 
because several studies have implicated these ATP-dependent assays as a gauge of metabolically 
active cells (96, 97). Luciferase activity in cells transfected with the scramble and vehicle only 
exposed cells served as the baseline indicators of cell viability. Compared to the scrambled 
control siRNA, we observed greater cell death (50-78%) in the Cos7-pGL4.16-ACSL4WT cells 
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transfected with siRNA 13.1. The cytotoxic effects of siRNA-RXR⍺ KD in Cos7 cells are 
consistent with reports in RXR⍺ knockout mice showing embryonic lethality (95).  
In line with our previous PUFA exposure experiments with Cos7-ACSL4-PPREKO cells 
(Figure 2), no significant differences in luciferase activity were observed in these cells 
transfected with the non-targeting scramble siRNA (Figure 7B). Similar results were also seen in 
Cos7-ACSL4 PPREKO cells transfected with siRNA 13.1, but cell survival was substantially 
reduced (Figure 7B). Like the Cos7-ACSL4-WT and Cos7-pGL4.16 cells transfected with 
siRNA 13.1, the increase in cell mortality is likely due to the inhibition of RXR⍺’s essential 
regulative functions in cellular metabolism. While the normalization of ACSL4 transcription in 
stably transformed Cos7 cells could be the consequence of RXR⍺ KD, it is more likely to be the 
product of increased cell death. Thus, without the ability to specifically implicate the underlying 
mechanism, we were unable to conclude that these data provide evidence that the PUFA-

















Table 2: Duplex siRNA sequences for the Knockdown of RXR⍺ in Cos7 cells 
Duplex siRNA Length (nt) Position Sequence 
13.1 27 3’ UTR CUAAUAUUUAGAGAGGAUGACAGA 
13.2 27 3’ UTR UCUAAAAGACUCUUGGAAUCUGAGA 
13.3 27 CDS GGCAAGGACCGGAACGAGAAUGAGG 
 
Table 3: Primers for amplification of target (RXR⍺) and non-target (HPRT1) genes in RT-
qPCR verification of siRNA-mediated KD of RXR⍺ in Cos7 cells 
Primer Length Sequence 
Human RXR⍺ F1 20 GAACTCCTCCCTCACCTCCC 
Human RXR⍺ R1 20 GCTGATGACCGAGAAAGGCG 
Human HPRT1 F1 25 GTTTTCCTAGAAAGCACATGGAGAGC 
Human HPRT1 R1 23 CCACAGTGTCAATGTTGTGATGC 
 
Figure 6: siRNA13.1 effectively reduces RXR⍺ expression in Cos7 cells  





Figure 7: Knockdown of RXR⍺ in Cos7 cells provided inconclusive evidence that the 
PUFA-mediated reduction in ACSL4 transcription is RXR-dependent 
A: Luciferase activity as a fold of the vehicle in Cos7-ACSL4-WT transfected with the scramble 
and siRNA 13.1 after 24 hours of FA exposure (mean ± SEM; n=3).  
B: Luciferase activity as a fold of the vehicle in Cos7-ACSL4-PPREKO transfected with the 
scramble and siRNA 13.1 after 24 hours of FA exposure (mean ± SEM; n=3). 
 
 
* No statistically significant differences were observed through comparison tests  
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Knockdown of RXR⍺ in Stably Transformed Cos7 Cells Provided Inconclusive Evidence 
that the PPAR⍺-mediated Reduction in ACSL4 transcription involves RXR. 
Transient KD of RXR⍺ in stably transfected Cos7 cells provide inconclusive evidence 
that RXR is necessary for PUFAs to reduce ACSL4 transcription. To determine if the observed 
cytotoxicity following RXR⍺ KD was specific to cells exposed to PUFA, we repeated siRNA-
mediated KD of RXR in Cos7-ACSL4-WT and Cos7-ACSL4-PPREKO before exposing the 
cells to the PPAR⍺ agonist, clofibrate. In the absence of cytotoxicity, we predicted that 
transfection with siRNA 13.1 would not affect ACSL4 promoter luciferase activity if PPAR⍺-
RXR⍺ heterodimer binding to PPRE in the ACSL4 promoter was responsible for the reduction of 
ACSL4 transcription observed in Figure 3A.  
In line with our previous PPAR agonist experiments, luciferase activity in Cos7-ACSL4-
WT cells transfected with the scramble siRNA was significantly reduced in a dose-dependent 
manner when exposed to clofibrate (Figure 8A). In contrast, luciferase activity was reduced in 
the same cells transfected with siRNA 13.1, but cell survival declined by 60-73%.  In Cos7-
ACSL4-PPREKO cells transfected with either the scramble or siRNA 13.1, luciferase activity 
was unaffected following clofibrate exposure (Figure 8B), however, cell death increased in cells 
transfected with siRNA 13.1 compared to the scramble. These results confirmed our prior 
experiments and suggest that while the PUFA-mediated reduction in ACSL4 transcription may be 
due to PPAR⍺ heterodimerization with RXR⍺, the observed cytotoxicity in siRNA-RXR⍺ 
transfected cells obscures this conclusion. Without further experimental modifications, we were 
unable to confirm that the PPAR⍺-RXR⍺ heterodimer regulates human ACSL4.		
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Figure 8: Knockdown of RXR⍺ in Cos7 cells provided inconclusive evidence that the 
PPAR⍺-mediated reduction in ACSL4 transcription is RXR-dependent 
A: Luciferase activity as a fold of the DMSO control in Cos7-ACSL4-WT transfected with the 
scramble and siRNA 13.1 after 24 hours of clofibrate exposure (mean ± SEM; n=3).  
B: Luciferase activity as a fold of the DMSO control in Cos7-ACSL4-PPREKO transfected with 








To evaluate the role of PUFAs as transcriptional regulators of human ACSL4, we first 
exposed stably transfected Cos7 cells (Cos7-pGL4.16, Cos7-ACSL4-WT, and Cos7-ACSL4-
PPREKO) to 50 µM albumin-conjugated FAs or a EtOH: H2O vehicle for 24-, 48-, and 72-hours. 
Through differences in observed luciferase activity between Cos7-ACSL4-WT and Cos7-
ACSL4-PPREKO cells, we concluded that PUFAs reduce ACSL4 transcription through a PPRE-
dependent pathway. We then explored potential mechanisms by which PUFAs could induce 
transcriptional changes in ACSL4 by exposing stably transfected Cos7 cells to specific PPAR 
agonists. Collectively, we found that PPAR⍺-mediated transrepression and PPARγ-mediated 
transrepression of ACSL4 are PPRE-dependent and PPRE-independent respectively, but our data 
did not implicate PPARβ/𝛿 in the regulation of ACSL4. After showing both PUFA and activated 
PPAR⍺ could regulate ACSL4 transcription through PPRE-dependent repression, we aimed to 
link these associations by examining luciferase activity in stably transfected Cos7 cells after 
transient KD of RXR⍺, the obligate partner of both PPAR⍺ and PPARγ.	Exposing cells to either 
FA or PPAR⍺ agonist after siRNA-RXR⍺ KD resulted in inconclusive findings as RXR⍺ KD 











Interpretation of Major Findings  
The primary objective of this work was to determine how dietary PUFAs contribute to 
the impairment of GSIS through their effects on the transcription of ACSL4, a key rate-limiting 
enzyme at the interface of lipid and carbohydrate metabolism. Our study provides evidence that 
PUFAs inhibit GSIS by a PPRE-dependent reduction in ACSL4 transcription through PPAR-
RXR heterodimerization. We propose the PUFA-mediated reductions in ACSL4 promoter 
activity prevent the normal ACSL4-mediated esterification of AA and AA-metabolites into 
glycerophospholipids, allowing the accumulation of unesterified EETs that reduce GSIS as 
reported in the literature (71). Thus, these findings outline a potential molecular mechanism 
coupling the repressive nutrigenomic effects of ω-6 PUFAs to the pathogenesis of T2DM.  
The results of this work are consistent with previous reports from our lab and others that 
describe the metabolic effects of dietary ω-6 PUFAs (71, 81). Exposure to AA and its precursor 
LA have been associated with reduced GSIS both in vitro (70-72, 76, 81, 82) and in vivo (73-77). 
By challenging stably transformed Cos7 cells with PUFAs for 24-, 48-, and 72-hours, we showed 
that ω-6 PUFAs reduce ACSL4 transcription independent of exposure duration (Figure 1) and 
that the mechanism is both PPRE-dependent and transrepressive, since PUFA exposure 
following the removal of PPRE sites in the pGL4.16-ACSL4-PPREKO reporter did not reduce 
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ACSL4 promoter activity (Figure 2). While these findings are in line with those in the literature 
that PPARs can regulate ACSL4 (90, 91), one study has reported that ω-6 PUFAs do not repress 
ACSL4 mRNA (81).  
Kan et al. 2014 reported that ACSL4 substrates like AA decrease ACSL4 protein, but not 
mRNA, both in vivo and in vitro. For their experiments, the investigators first compared ACSL4 
expression in liver tissues from two sets of C57BL/6J male mice fed either a normal chow diet 
(NCD) or a high-fat diet (HFD) (60% total fat, with 36% saturated, 41% monounsaturated, and 
23% polyunsaturated fats) for 16 weeks. While both sets of C57BL/6J mice fed the HFD showed 
a decrease in ACSL4 protein levels, ACSL4 mRNA was significantly reduced in the larger group 
of mice (n=5 per dietary condition), but not the smaller group (n = 3 per dietary condition). Next, 
the authors tried to identify the underlying mechanisms involved in the repression of ACSL4 
expression observed in these mice by challenging immortalized human hepatic cell lines (HepG2 
and Huh7) with a FA mixture (65 μM PA, 65 μM OA, and 20 μM AA) for 24 hours before 
evaluating ACSL4 mRNA and protein expression. Following exposure, the investigators showed 
that ACSL4 protein was reduced by 37-72% in both cell lines, while ACSL4 mRNA was only 
reduced in HepG2 cells.  
Given their inconsistent findings on the effects of these dietary fats on ACSL4 mRNA, 
the authors attempted a final set of experiments in HepG2 cells to determine if FA exposure 
modulates ACSL4 transcription. First, ACSL4 mRNA was evaluated in the presence of a 
transcription inhibitor (actinomycin D) and it was found that mRNA levels were unchanged both 
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in control cells and those challenged with 50 µM AA. Second, ACSL4 promoter activity was 
examined by comparing luciferase activity in transiently transfected HepG2 cells exposed to 5 
µM AA, 50 µM AA, or a vehicle for 24 hours. Similar to the previous experiment, the authors 
did not observe a significant difference in luciferase activity between transfected HepG2 cells 
incubated with AA or the vehicle and thus concluded that ACSL4 substrates had no effect on 
ACSL4 transcription.  
Although Kan et al. utilized multiple molecular techniques to show ACSL4 transcription 
is unaffected by PUFA exposure, their findings remain contentious for several reasons. Aside 
from the inconsistent results in the in vivo arm of their study, the investigators’ methods of 
examining ACSL4 transcription in vitro were not sufficient to produce reliable results. In their 
first experiment with actinomycin D, Kan et al. ignored the possibility that the single- and 
double-stranded breaks (DSBs) initiated by actinomycin D could themselves impact ACSL4 
transcription. For instance, Lei et al. 2020 (120) showed that both ACSL4 mRNA and protein is 
significantly upregulated in response to DSBs, an effect that could have produced atypical 
transcription in the Kan et al. study.  
Furthermore, Kan et al.’s use of a transiently transfected pGL3 luciferase vector to 
examine ACSL4 promoter activity is problematic as these reporters have been noted by the 
manufacturer (Promega, Madison, WI) to have lower intracellular luciferase expression in 
eukaryotic cells, a higher risk of anomalous transcription from cryptic regulatory sites (see 
Figure S7 in appendix), and significantly reduced signal-to-noise ratios (373- to 6388-fold less) 
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when compared to Promega’s redesigned and improved pGL4 luciferase reporter (121). Unlike 
Kan et al., however, our work has produced more reliable results on ACSL4 transcription 
because we used a pGL4 luciferase reporter (pGL4.16) instead of a pGL3 series vector. 
Additionally, our in vitro analysis of ACSL4 promoter activity is strengthened by our use of 
stably transfected Cos7 cell lines, rather than transiently transfected cell lines like those 
employed by Kan et al, as ACSL4 expression levels were less likely to fluctuate from reporter 
degradation by nucleases or dilution from cell division.  
While our data more firmly establish that ω-6 PUFA exposure can reduce ACSL4 
transcription, we also unexpectedly found that ACSL4 expression could be repressed by ω-3 
PUFA exposure (EPA, DHA) in Cos7 cells (Figure 1). Studies evaluating the metabolic effects 
of ω-3 PUFA exposure have described these PUFAs as overwhelmingly beneficial to human 
health, noting they increase glucose tolerance (99, 100) and insulin secretion (99, 100), while 
decreasing the production of inflammatory eicosanoids (100, 101). If a reduction in ACSL4 
transcription is responsible for the impairment of GSIS in T2DM, then we anticipated that ω-3 
PUFA exposure would not downregulate ACSL4.  To explain the unexpected ω-3 PUFA-
mediated repression of ACSL4 transcription we observed, it is possible ω-3 PUFAs could 
independently enhance GSIS by modulating the intracellular eicosanoid profile. Recent studies 
have shown that the same CYP 450 enzymes that epoxidize AA, also metabolize EPA and DHA 
to epoxyeicosatetraenoic acids (EEQs) and epoxydocosapentaenoic acids (EDPs), respectively 
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(102, 103). EEQs and EDPs have been reported to potently oppose the inflammatory actions of 
EETs (104).  
Given that the more dominant PUFA species ultimately drives the production of its own 
eicosanoid metabolites, the ratio of dietary ⍵-6 PUFA to ⍵-3 PUFA (n-6: n-3) has become a 
marker for the risk of developing metabolic and cardiovascular disorders (65, 66). A greater 
dietary n-6: n-3 ratio is associated with the stimulation of inflammatory pathways that are 
prothrombotic and proaggregatory (66), while a lower n-6: n-3 ratio leads to the dominance of 
anti-inflammatory resolvins, protectins, and maresins (65). Evolutionary studies have estimated 
that the n-6: n-3 ratio of the human diet was historically 1:1, but advocacy efforts throughout the 
20th century by U.S. health agencies to increase ω-6 PUFA consumption (10-14) have helped 
increase the modern Western diet n-6: n-3 ratio to an average of 10: 1 (122).  
The rise of the dietary n-6: n-3 ratio is contributing to the increased incidence of chronic 
metabolic disease, yet our finding that both ⍵-3 and ⍵-6 PUFA species reduce ACSL4 
transcription is important as it suggests the possibility of adverse physiological effects from the 
overconsumption of ω-3 PUFAs. Few studies have examined an upper limit to the intake of 
dietary ω-3 PUFAs, but those that have, report that such overconsumption can stimulate an 
increase in serum glucose (123), significantly decrease coagulation (124), and reduce blood 
pressure (125). Taken together, our study and others (123-125) suggest that the consumption of 
dietary PUFA species may indeed be governed by the Goldilocks Principle, whereby moderation 
of ⍵-6 PUFA and ⍵-3 PUFA intake produces optimal metabolic effects.  
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In addition to identifying dietary lipids that could affect ACSL4 transcription, this work 
also sought to determine what role PPARs play in the PUFA-mediated impairment of GSIS. We 
exposed stably transformed Cos7 cells to agonists of all three PPAR isoforms and our results 
suggest that PPARs differentially regulate ACSL4 transcription. After PPAR⍺ agonist (clofibrate 
or WY-14643) exposure, we found ACSL4 transcription was only significantly reduced in Cos7-
ACSL4-WT reporters that contained PPRE binding sites (Figure 3). Like our PUFA exposure 
results, we interpreted this as an indication that the transrepression of ACSL4 transcription by 
PPAR⍺ is PPRE-dependent.  
Several studies have addressed the regulatory effects of PPAR⍺ agonists (clofibrate and 
WY-14643) on ACSL4 and the consensus appears to be that PPAR⍺ regulation is tissue- and 
cell-specific and can occur through differential transcriptional, translational, or post-translational 
control mechanisms (91, 105-108). For example, at a transcriptional and translational level, Kan 
et al. reported that the exposure of primary human hepatocytes to 50 µM WY-14643 (10 times 
higher than the EC50) does not significantly affect ACSL4 mRNA levels, but increases ACSL4 
protein by 30% (88). However, these results are difficult to interpret as an increase in ACSL4 
protein was only observed in one of the two cell lines the investigators examined and the 
concentration of WY-14643 used likely activates both PPARβ/𝛿 and PPAR⍺	(108). Further, Kan 
et al. used a pGL3 luciferase reporter to analyze ACSL4 transcription after PPAR activation and 
the drawbacks of these vectors have been previously described. At a post-translational level, Kim 
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et al. showed that the PPAR⍺ agonist	clofibrate (up to concentrations of 50 µM) had no effect on 
recombinant purified rat ACSL4 acyl-CoA synthetase activity (105).  
Unlike the findings in Kan et al., our study using a more reliable luciferase reporter 
provides evidence that ACSL4 transcription is reduced in a dose-specific manner following either 
clofibrate or WY-14643 exposure in Cos7-ACSL4-WT cells. Further, when comparing our 
results to those of Kan et al., we challenged stably transformed Cos7 cells with concentrations of 
PPAR⍺ agonists (20-100 µM clofibrate or 2.5-10 µM WY-14643) that solely activate PPAR⍺, 
whereas Kan et al. used PPAR agonist concentrations (50 µM WY-14643) that would activate 
both PPARβ/𝛿 and PPAR⍺. Another important distinction between our study and that of Kan et 
al. was our focus on ACSL4 promoter activity, rather than ACSL4 mRNA. mRNA transcripts 
have been traditionally used to assess transcription, but the stability of these gene products differ 
across cell types and are often sensitive to degradation. Our examination of ACSL4 promoter 
activity, however, allowed us to more accurately show how differences in promoter architecture 
(i.e., sequences with or without PPRE motifs) affect the presence of transcription factors that 
could modulate downstream gene expression.  
In addition to PPAR⍺, we examined the effects of PPAR β/𝛿 agonist exposure in stably 
transformed Cos7 cells. Kan et al. reported that PPAR β/𝛿 agonists (both L-165041 and 
GW0742) increased ACSL4 mRNA and ACSL4 protein in hepatocytes (91). Although we used 
the same PPAR β/𝛿 agonists, we did not reach the same conclusions, but it was difficult to 
compare our study to those in the literature due to differences in the cell lines and the luciferase 
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reporters. Instead of an increase in ACSL4 expression, we found that exposure to GW0742 (0.5-1 
µM) or L-165041 (25-100 µM) in both Cos7-ACSL4-WT and Cos7-ACSL4-PPREKO cells did 
not alter ACSL4 transcription as measured by luciferase activity (Figure 4). While Kan et al.’s 
use of a pGL3 luciferase reporter rather than one from the improved pGL4 series is a possible 
explanation for the observed difference in ACSL4 transcription, another could be that PPARβ/𝛿 
protein expression levels in Cos7 cells are different than those in HepG2 cells.  
The final agonist we used to evaluate the regulatory role of PPARs in ACSL4 
transcription was rosiglitazone, a potent PPARγ agonist (EC50 < 1µM, 108). Until this study, 
only the effects of rosiglitazone on purified recombinant rat ACSL4 acyl-CoA synthetase activity 
have been reported (105, 109, 110). Kim et al. 2001 and Askari et al. 2007 both determined that 
the rosiglitazone-mediated regulation of ACSL4 is PPARγ-independent, as rosiglitazone directly 
suppresses ACSL4 ACS-activity as a non-competitive inhibitor. Although the reduction of 
ACSL4 ACS-activity by rosiglitazone is PPARγ-independent, our study suggests that the ACSL4 
promoter is regulated by PPARγ activation. After exposing stably transformed Cos7 cells to 10-
100 µM of rosiglitazone, ACSL4 transcription was reduced independent of dose in both Cos7-
ACSL4-WT and Cos7-ACSL4-PPREKO cells (Figure 5). These results, alongside the absence 
of normalized ACSL4 transcription in Cos7-ACSL4-PPREKO cells, led us to conclude that 
PPARγ regulates ACSL4 transcription through a PPRE-independent mechanism.   
By examining the effects of PPAR agonists on ACSL4, we identified one PPAR isoform 
(PPAR⍺) that was, like PUFAs, capable of reducing ACSL4 transcription in a PPRE-dependent 
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manner. One of the mechanisms PUFAs use to carry out their regulatory functions involves their 
binding to and activation of PPARs, but there is evidence they also serve as ligands for other 
nuclear receptors like RXRs, RARs, LXRs, SREBP-1, ChREBP, and MLX (77). To rule out the 
possibility that the PUFA-mediated reduction of ACSL4 transcription does not depend on the 
binding of non-PPAR nuclear receptors, we re-evaluated PUFA and PPAR⍺ agonist exposure in 
stably transformed Cos7 cells with a transient KD of RXR⍺.  
RXR isoforms (RXRɑ, RXRβ, and RXR𝛾) are obligate partners of PPAR and their 
absence prevents PPARs from carrying out their regulatory effects on transcription (94, 95). We 
reasoned that because RXR⍺ can bind either PPAR⍺ or PPARγ, the KD of RXR⍺ by siRNA 
would normalize ACSL4 transcription. As expected, ACSL4 transcription was reduced in stably 
transformed Cos7 cells transfected with the siRNA non-targeting scramble after exposure to 
PUFA (Figure 7) or PPAR⍺ agonist (Figure 8), but not in Cos7 cells with the transient KD of 
RXR⍺. While these data provided evidence that the activated PPAR⍺-RXR⍺ heterodimer could 
mediate the PUFA reduction in ACSL4 promoter activity, cytotoxicity with RXR⍺ KD did not 
allow us to make any conclusions. The cytotoxicity observed underscores the significance of this 
transcription factor for cell viability. Thus, without further experimental modifications, we 
cannot determine if the observed changes in ACSL4 transcription were due to the downregulation 





Limitations   
This work has identified PPAR⍺ as a nuclear receptor responsible for the PUFA-
mediated reduction in ACSL4 transcription. In the context of these findings, this study has 
several limitations. First, the role of the human ACSL4 promoter in the regulation of transcription 
was evaluated by its ability to drive the expression of the Luc2CP gene. Luciferase activity in 
transfected cells served as an indicator of Luc2CP expression, and by extension, ACSL4 
transcription. While this method is advantageous because of its sensitivity to transcriptional 
changes, luciferase is also a bifunctional enzyme, possessing both acyl-CoA synthetase and 
ATP-dependent monooxygenase activity (111). Studies have shown that firefly luciferase has a 
significant preference for the activation of AA, followed by LA, OA, and PA (111). Although 
light is not generated by the acyl-CoA synthetase activity of luciferase, we anticipated luciferase 
could still compete with endogenous ACSL4 for the activation of FAs.  
To account for any potential confounding effects of luciferase’s endogenous acyl-CoA 
synthetase activity on our analysis, Cos7 cells with low basal ACSL4 expression (61) were 
transfected with a specialized luciferase (luc2CP) designed by Promega (Madison, WI) 
containing protein degradation signals (CL1 and PEST). CL1 and PEST reduce the half-life of 
luc2CP protein to approximately 24 minutes and thereby more effectively couple changes in 
luciferase activity to the triggering event (112). For comparison, ACSL4 protein half-life has 
been shown to be on the magnitude of several hours (81). While this does not entirely account 
for all of the substrates that luciferase could catalyze, we assumed the effects of other reactions 
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would be mitigated by luc2CP’s rapid turnover rate and that light generated by luc2CP for each 
assay was at steady-state.  
In addition to the reporters, the sequence of each ACSL4 promoter we used in our 
analysis limited the conclusions we could make, as the ACSL4-PPREKO promoter (1.2 kbp, 0 
PPRE motifs) is a truncated version of the ACSL4-WT promoter (2.4 kbp, 5 PPRE motifs). 
These reporters were used to examine the effects of PPRE-dependent transcription, however, a 
more effective pGL4.16-ACSL4-PPREKO reporter would have been identical to pGL4.16-
ACSL4-WT, but without PPRE motifs. This could have been accomplished by site-directed 
mutagenesis, but instead we removed PPRE motifs in the distal promoter region (-2426 to -1162 
relative to the TSS) through restriction enzymes (Xho1, HindIII, and Kpn1). The most significant 
consequence of this decision is that important transcription factor binding sites for other 
regulatory nuclear receptors (RXRs, RARs, LXRs, SREBP-1, ChREBP, and MLX) could have 
been removed from the ACSL4 promoter. Even if this were true, the changes in ACSL4 
transcription that we observed after removing the PPRE motifs provided definitive proof that the 
distal promoter of ACSL4 is essential for its regulation.   
Finally, the dietary FA exposure methodology we used to evaluate ACSL4 transcription 
has a few drawbacks. Cells are never exposed to large concentrations of a single FA, but rather 
under normal physiologic conditions the extracellular environment contains a mixture of SFAs, 
MUFAs, PUFAs, and other lipid species. Our experiments provided insight into how isolated 
FAs could affect ACSL4 expression, but future studies should evaluate the transcriptional effects 
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of FA combinations in different FA delivery environments as to be more generalizable. More 
specifically, studies have shown that the biological effects of unesterified FAs are dependent 
upon the molar ratio of FA to BSA and the FA conjugation efficiency in culture medium as the 
fraction of unbound FA available for cellular uptake differs for each condition (126, 127). While 
all of our experiments utilized a 1:1 molar ratio of FA to BSA, we could have used medium with 
varying FA to BSA ratios up to 5:1 to determine if quantitative differences in unbound FAs in 


















FUTURE DIRECTIONS  
The results of this work provide further evidence that PUFAs reduce ACSL4 transcription 
through PPAR-dependent regulation. To overcome the weaknesses of our study, future 
experiments would examine how specific PPAR isoforms affect ACSL4 transcription. We 
utilized an siRNA-induced transient RXR⍺ KD in Cos7 cells to address how PPAR-RXR⍺ 
heterodimers regulate ACSL4, but the cytotoxicity observed in cells with siRNA RXR⍺ KD 
severely limits our ability to make conclusions. An alternative approach to determine which 
PPAR isoform(s) is implicated in the PUFA-mediated impairment of ACSL4 transcription would 
be to downregulate the specific PPAR isoforms (PPARɑ, PPARβ/𝛿, and PPAR𝛾) by siRNA, as 
unlike RXR⍺ KD, knockout of the PPAR isoforms does not cause cytotoxicity (113-115). If our 
PPAR heterodimer hypothesis is correct, we would expect ACSL4 transcription to be unaffected 
in PPAR isoform KD cells after PUFA or PPAR agonist exposure.  
This study has identified two PPAR isoforms as regulators of human ACSL4 (PPARɑ, 
and PPAR𝛾), but the effects of PPARβ/𝛿 were inconclusive. Numerous studies (88, 116-118) 
have implicated PPARβ/𝛿 as a therapeutic target in metabolic disorders, in that the PPARβ/𝛿 
protects against obesity by reducing dyslipidemia and insulin resistance (116, 117). Studies have 
directly evaluated the PPARβ/𝛿 regulatory effects on the transcription of ACSL4 where in vitro 
(hepatocytes, 91) and in vivo (mammary tissue, 118) differential enhancement of ACSL4 
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transcription was observed after GW0742, GW501516 and L165041 exposure. Given our 
inconclusive results, future experiments should clarify how the activation of PPARβ/𝛿 regulates 
ACSL4 transcription in different tissue/cell types.  
Finally, our study provides a foundation for future experiments to more closely examine 
corepressor candidates associated with the transcriptional regulation of ACSL4. We previously 
proposed that SMRT, SHARP, and HDACs could be recruited by the PPAR-RXR heterodimer 
following its binding to PPRE in the ACSL4 promoter, however, the range of transcription 
factors and subsequent molecular mechanism involved with each PPAR isoform and cell type are 
different (106). To provide insight into our previous predictions, future probes should focus on 
using chromatin immunoprecipitation assays (ChIP) to identify methylation patterns and 
associated corepressors in the wild-type ACSL4 promoter following exposure to a PUFA or 
PPAR agonist.   
Despite our inability to implicate RXR⍺ in the PUFA-mediated reduction of ACSL4 
transcription, this work firmly establishes that PUFAs downregulate ACSL4 transcription in part 
through PPRE-dependent PPAR⍺ activation and PPRE-independent PPARγ activation. These 
findings not only demonstrate that the intake of dietary FAs has species-specific metabolic 
consequences, but also that the overconsumption of PUFAs could be contributing to the modern 
epidemic of chronic metabolic diseases. To counteract these apparent ill-effects, future nutrition 
policy reinforcing the diet-heart hypothesis should be replaced with guidelines encouraging the 
reduced intake of ω-6 PUFA rich oils that have become so prominent in the Western diet. 
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Furthermore, our identification of a molecular mechanism coupling the consumption of dietary 
PUFAs to the impairment of GSIS suggests the use of PPAR agonists as attractive therapeutic 
targets. While our understanding of the complete molecular machinery responsible for the 
regulation of ACSL4 is far from clear, clarifying how these underlying mechanisms dysregulate 
carbohydrate and lipid metabolism will only serve to strengthen future efforts to prevent and 

















APPENDIX: SUPPLEMENTAL DATA 
 
Figure S1: SCS data from 22 countries shows a weaker correlation than what Keys presented  
Left: Graphics provided by Keys in the original SCS publication showing a strong correlation 
between FA consumption as total calories and corresponding deaths by heart disease.  
Right: Mortality as it relates to sugar and saturated fat consumption from all of the countries that 

















Figure S2: FA metabolism and partitioning in the cell  
Sources of non-esterified FA (NEFAs) like exogenous FA and endogenous FA, are either 
activated by ACSLs or channeled towards eicosanoid synthesis and regulation pathways. If 
activated by an ACSL, the resultant acyl-CoA can be modified or used for synthesis, energy 










Figure S3: Preparation of source vector pcDNA3.1-Hygro (-) 
A: Circular pcDNA3.1 (lane 2) was digested with HindIII and Xho1 (lanes 3-5), Xba1-Apa1 
(lanes 6-8), or Apa1 (lanes 9-11) 
B: The human ACSL4 promoter (2482 bp) insert was amplified by PCR and digested with 
restriction sites for its respective backbone.  
C: Circular pcDNA3.1-Hygro (-) (lane 2), unsuccessful integration of the ACSL4 promoter with 
pcDNA3.1-Hygro (-) following Apa1 digestion (lane 3-5). Successful combination of the ACSL4 







Figure S4: Preparation of pGL4.16-ACSL4-WT and pGL4.16-ACSL4-PPREKO 
A: Undigested pGL4.16 (lane 2), empty pGL4.16 vector (6020 bp) following an unsuccessful 
integration of the ACSL4 promoter (2482 bp) insert using with Xho1 and HindIII (lanes 3-4), and 
complete pGL4.16-ACSL-WT following digestion with Xho1 and HindIII (lanes 5-8)   
B: Untreated pGL4.16-pGL4.16-PPREKO (lane 2) and successful integration of the 







Figure S5: Design of pGL4.16 luciferase reporters 
A: Promoterless pGL4.16. The Xho1 (33) and HindIII (65) restriction sites (boxed in red) were 















Figure S5: Design of pGL4.16 luciferase reporters 
B: pGL4.16 containing the wild type human ACSL4 promoter (2482 bp) inserted at +34 relative 
to the multiple cloning start sequence by the Xho1 and HindIII restriction sites. KpnI sites (14, 
1293) bookend the distal ACSL4 promoter containing 5 PPRE motifs (marked inside the vector 










Figure S5: Design of pGL4.16 luciferase reporters  
C: Wild type human ACSL4 distal promoter sequence (-2426 to -1162 relative to the TSS) 




Figure S5: Design of pGL4.16 luciferase reporters  
D: pGL4.16 containing the PPREKO human ACSL4 promoter (1218 bp). Kpn1 restriction 
enzyme sites bookending the wild type human ACSL4 promoter (B) were used to excise PPRE 








Figure S6: Kill curve data for Hygromycin B exposure in Cos7 cells 
Viable Cos7 cells were counted on day 1 and day 7 after exposure to Hygromycin B (50-600 

















Figure S7: Comparison of consensus transcription factor binding sites in  
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